Research graph
References from Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR. Local targets link to admitted publications; unresolved targets remain external evidence.
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
10.1093/ndt/gfz054 · 2020 · External reference
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease
10.1111/j.1523-1755.2005.00395.x · 2005 · External reference
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
10.1016/s0140-6736(13)61407-5 · 2013 · External reference
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial
10.1371/journal.pmed.1002777 · 2019 · External reference
Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial
10.1001/jama.2018.15870 · 2018 · External reference
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease
10.1016/j.kint.2026.05.018 · 2026 · External reference
GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials
10.1681/asn.2019010007 · 2019 · External reference
Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials
10.1371/journal.pone.0257606 · 2021 · External reference
Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease
10.1053/j.gastro.2019.04.018 · 2019 · External reference
Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study
10.1007/s40264-016-0486-x · 2017 · External reference
Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation
10.1007/s40268-021-00342-7 · 2021 · External reference
Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease
10.1002/sim.8282 · 2019 · External reference
Change in measured GFR versus eGFR and CKD outcomes
10.1681/asn.2015040341 · 2016 · External reference
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2025 · External reference
Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial
10.1001/jama.2018.15870 · ExternalCitation · doi-reference
Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease
10.1002/sim.8282 · ExternalCitation · doi-reference
Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study
10.1007/s40264-016-0486-x · ExternalCitation · doi-reference
Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation
10.1007/s40268-021-00342-7 · ExternalCitation · doi-reference
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease
10.1016/j.kint.2026.05.018 · ExternalCitation · doi-reference
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
10.1016/s0140-6736(13)61407-5 · ExternalCitation · doi-reference
Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease
10.1053/j.gastro.2019.04.018 · ExternalCitation · doi-reference
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
10.1093/ndt/gfz054 · ExternalCitation · doi-reference
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease
10.1111/j.1523-1755.2005.00395.x · ExternalCitation · doi-reference
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial
10.1371/journal.pmed.1002777 · ExternalCitation · doi-reference
Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials
10.1371/journal.pone.0257606 · ExternalCitation · doi-reference
Change in measured GFR versus eGFR and CKD outcomes
10.1681/asn.2015040341 · ExternalCitation · doi-reference
GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials
10.1681/asn.2019010007 · ExternalCitation · doi-reference
